MUMBAI, India, April 20 -- Intellectual Property India has published a patent application (202617011442 A) filed by Ablynx Nv; and Sanofi, Zwijnaarde, Belgium, on Feb. 3, for 'improved fcrn antagonists for treatment of igg-related diseases and disorders.'
Inventor(s) include Van Bogaert, Tom; and Verhelst, Judith.
The application for the patent was published on April 17, under issue no. 16/2026.
According to the abstract released by the Intellectual Property India: "The present invention relates to FcRn antagonists which bind to the neonatal Fc receptor (FcRn) and interfere with binding of FcRn's natural ligands, the Fc region of IgG. In particular, the invention relates to FcRn antagonists comprising at least one first polypeptide specifically binding to an epitope on Fc receptor (FcRn) and a second polypeptide which competes with wild-type IgG1 Fc region for binding to FcRn. The invention also relates to fusion proteins comprising the FcRn antagonists, compositions comprising the FcRn antagonists and/or fusion proteins and the use of the FcRn antagonists, compositions comprising the FcRn antagonists and/or fusion proteins in medicine, in particular in the treatment of IgG-mediated disorders."
The patent application was internationally filed on July 05, 2024, under International application No.PCT/EP2024/069101.
Disclaimer: Curated by HT Syndication.
